Treatment of Hemophilia A Patients With FVIII Inhibitors

Abroad (travel likely)Recruiting

Conditions

Hemophilia A

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Arthur M. Blank Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (Robert Sidonio, MD, MSc) · robert.sidonio.jr@emory.edu · 404-785-1637
Contact: Principal Investigator (Robert Sidonio, MD, MSc)
HZRM Hämophilie-Zentrum Rhein Main, Mörfelden-Walldorf, Germany
Contact: Study coordinator (Carmen Escuriola-Ettingshausen, MD) · carmen.escuriola@hzrm.de · +4961059638909
Contact: Principal Investigator (Carmen Escuriola-Ettingshausen, MD)

Study leads

Robert Sidonio, MD, MSc
Principal Investigator
Emory University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Hemophilia A

Abroad (travel likely)RecruitingPHASE3

Atlanta, United States · Atlanta, United States

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

Hemophilia A

Abroad (travel likely)Recruiting

Little Rock, United States · Palo Alto, United States

Pharmacokinetic-guided Dosing of Emicizumab

Hemophilia A With Inhibitor · Hemophilia A Without Inhibitor · Hemophilia A, Severe

Abroad (travel likely)RecruitingPHASE4

Nijmegen, Netherlands · Maastricht, Netherlands

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hemophilia A

Abroad (travel likely)RecruitingPHASE1, PHASE2

Orange, United States · Vallejo, United States